In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech: Advantaged In The Middle

Executive Summary

During Art Levinson's five-year tenure as CEO, Genentech has enjoyed its greatest period of commercial success. To get there, the company jump-started its pipeline by pouring huge sums into R&D. It was able to do so, in part, because of a put/call provision contained in its agreement with majority stakeholder Roche that, by setting a floor and a ceiling on share prices, insulated it from the usual market pressures to demonstrate earnings growth. With that protection now gone, and having given Roche an option on worldwide rights for its products, Genentech must either increase the productivity of an already impressive R&D operation or for the first time look to M&A to grow earnings, in order to achieve its goal of a five-fold sales increase by 2005. Still, Genentech's recent successes make a solid case for the viability of mid-sized companies and R&D -focused strategies in an era of consolidation.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts